Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms

The Journal of Antimicrobial Chemotherapy
Mariana CastanheiraRobert K Flamm

Abstract

Plazomicin is a next-generation aminoglycoside that was developed to overcome common aminoglycoside-resistance mechanisms. We evaluated the activity of plazomicin and comparators against clinical isolates collected from 26 European and adjacent countries during 2014 and 2015 as part of the Antimicrobial Longitudinal Evaluation and Resistance Trends (ALERT) global surveillance programme. All 4680 isolates collected from 45 hospitals were tested for susceptibility to antimicrobials using the reference broth microdilution method. Selected isolates were screened for genes encoding carbapenemases, aminoglycoside-modifying enzymes (AMEs) and 16S rRNA methyltransferases. Plazomicin (MIC50/90 0.5/2 mg/L) inhibited 95.8% of Enterobacteriaceae at ≤2 mg/L, including carbapenem-resistant Enterobacteriaceae (MIC50/90 0.25/128 mg/L). Plazomicin was more active compared with other aminoglycosides against isolates carrying blaKPC (MIC50/90 0.25/2 mg/L), isolates carrying blaOXA-48-like (MIC50/90 0.25/16 mg/L) and carbapenemase-negative isolates (MIC50/90 0.25/1 mg/L). Approximately 60% of the isolates harbouring blaVIM and blaNDM-1 carried 16S rRNA methyltransferases (mainly rmtB and armA). AME genes were detected among 728 isolates and 99.0% ...Continue Reading

References

Apr 2, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-LeclercqP M Tulkens
Jul 15, 2003·Clinical Microbiology Reviews·Sergei B Vakulenko, Shahriar Mobashery
Nov 10, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·P N Rather
Sep 23, 2009·Antimicrobial Agents and Chemotherapy·Andrea EndimianiRobert A Bonomo
Sep 14, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maria S Ramirez, Marcelo E Tolmasky
Nov 17, 2010·The Journal of Antimicrobial Chemotherapy·D M LivermoreN Woodford
Oct 18, 2011·Diagnostic Microbiology and Infectious Disease·Béatrice BerçotPatrice Nordmann
Apr 20, 2012·Expert Review of Anti-infective Therapy·George G ZhanelJames A Karlowsky
Jun 8, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jun-ichi Wachino, Yoshichika Arakawa
Oct 1, 2015·Expert Opinion on Investigational Drugs·Ilias KaraiskosHelen Giamarellou
May 22, 2016·Infectious Disease Clinics of North America·Yohei DoiYoshichika Arakawa

❮ Previous
Next ❯

Citations

Aug 23, 2019·Antibiotics·Beatriz Suay-García, María Teresa Pérez-Gracia
Dec 25, 2019·Journal of the Pediatric Infectious Diseases Society·Kathleen ChiotosPranita D Tamma
Mar 11, 2020·Antimicrobial Agents and Chemotherapy·Michael R JacobsUNKNOWN Antibacterial Resistance Leadership Group
Sep 5, 2019·Frontiers in Microbiology·Xiaoyan CuiHong Du
Aug 15, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Konstantina NafpliotiIrene Galani
Jul 1, 2020·Antimicrobial Agents and Chemotherapy·Zackery P BulmanLogan D Andrews
Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
Jan 28, 2021·Infection and Drug Resistance·Xing TanZackery P Bulman
Apr 4, 2021·Journal of Clinical Medicine·Erlangga YusufMireille van Westreenen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

© 2022 Meta ULC. All rights reserved